IBDEI2T9 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,44833,0)
;;=L23.9^^170^2237^2
;;^UTILITY(U,$J,358.3,44833,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44833,1,3,0)
;;=3^Eczema,Allergic Contact,Unspec
;;^UTILITY(U,$J,358.3,44833,1,4,0)
;;=4^L23.9
;;^UTILITY(U,$J,358.3,44833,2)
;;=^5009125
;;^UTILITY(U,$J,358.3,44834,0)
;;=L20.82^^170^2237^3
;;^UTILITY(U,$J,358.3,44834,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44834,1,3,0)
;;=3^Eczema,Flexural
;;^UTILITY(U,$J,358.3,44834,1,4,0)
;;=4^L20.82
;;^UTILITY(U,$J,358.3,44834,2)
;;=^5009109
;;^UTILITY(U,$J,358.3,44835,0)
;;=L20.84^^170^2237^4
;;^UTILITY(U,$J,358.3,44835,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44835,1,3,0)
;;=3^Eczema,Intrinsic
;;^UTILITY(U,$J,358.3,44835,1,4,0)
;;=4^L20.84
;;^UTILITY(U,$J,358.3,44835,2)
;;=^5009111
;;^UTILITY(U,$J,358.3,44836,0)
;;=L51.8^^170^2237^11
;;^UTILITY(U,$J,358.3,44836,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44836,1,3,0)
;;=3^Erythema Multiforme,Other
;;^UTILITY(U,$J,358.3,44836,1,4,0)
;;=4^L51.8
;;^UTILITY(U,$J,358.3,44836,2)
;;=^336639
;;^UTILITY(U,$J,358.3,44837,0)
;;=R23.4^^170^2237^15
;;^UTILITY(U,$J,358.3,44837,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44837,1,3,0)
;;=3^Eschar/Desquamination of Skin
;;^UTILITY(U,$J,358.3,44837,1,4,0)
;;=4^R23.4
;;^UTILITY(U,$J,358.3,44837,2)
;;=^5019296
;;^UTILITY(U,$J,358.3,44838,0)
;;=L49.9^^170^2237^25
;;^UTILITY(U,$J,358.3,44838,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44838,1,3,0)
;;=3^Exfoliation d/t Erythematous Cond w/ 90% or More Body Surface
;;^UTILITY(U,$J,358.3,44838,1,4,0)
;;=4^L49.9
;;^UTILITY(U,$J,358.3,44838,2)
;;=^5009199
;;^UTILITY(U,$J,358.3,44839,0)
;;=L74.9^^170^2237^1
;;^UTILITY(U,$J,358.3,44839,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44839,1,3,0)
;;=3^Eccrine Sweat Disorder,Unspec
;;^UTILITY(U,$J,358.3,44839,1,4,0)
;;=4^L74.9
;;^UTILITY(U,$J,358.3,44839,2)
;;=^5009296
;;^UTILITY(U,$J,358.3,44840,0)
;;=L98.7^^170^2237^16
;;^UTILITY(U,$J,358.3,44840,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44840,1,3,0)
;;=3^Excessive/Redundant Skin/Subq Tissue
;;^UTILITY(U,$J,358.3,44840,1,4,0)
;;=4^L98.7
;;^UTILITY(U,$J,358.3,44840,2)
;;=^5138778
;;^UTILITY(U,$J,358.3,44841,0)
;;=L72.0^^170^2237^7
;;^UTILITY(U,$J,358.3,44841,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44841,1,3,0)
;;=3^Epidermal/Epidermoid Cyst
;;^UTILITY(U,$J,358.3,44841,1,4,0)
;;=4^L72.0
;;^UTILITY(U,$J,358.3,44841,2)
;;=^5009277
;;^UTILITY(U,$J,358.3,44842,0)
;;=L92.3^^170^2238^1
;;^UTILITY(U,$J,358.3,44842,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44842,1,3,0)
;;=3^FB Granuloma Skin/Subcutaneous Tissue
;;^UTILITY(U,$J,358.3,44842,1,4,0)
;;=4^L92.3
;;^UTILITY(U,$J,358.3,44842,2)
;;=^5009464
;;^UTILITY(U,$J,358.3,44843,0)
;;=L66.2^^170^2238^4
;;^UTILITY(U,$J,358.3,44843,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44843,1,3,0)
;;=3^Folliculitis Decalvans
;;^UTILITY(U,$J,358.3,44843,1,4,0)
;;=4^L66.2
;;^UTILITY(U,$J,358.3,44843,2)
;;=^5009254
;;^UTILITY(U,$J,358.3,44844,0)
;;=L73.9^^170^2238^3
;;^UTILITY(U,$J,358.3,44844,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44844,1,3,0)
;;=3^Follicular Disorder,Superficial
;;^UTILITY(U,$J,358.3,44844,1,4,0)
;;=4^L73.9
;;^UTILITY(U,$J,358.3,44844,2)
;;=^5009286
;;^UTILITY(U,$J,358.3,44845,0)
;;=L02.221^^170^2238^5
;;^UTILITY(U,$J,358.3,44845,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2T9 3755 printed Sep 23, 2025@20:11:24 Page 2
IBDEI2T9 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,44833,0)
+2 ;;=L23.9^^170^2237^2
+3 ;;^UTILITY(U,$J,358.3,44833,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,44833,1,3,0)
+6 ;;=3^Eczema,Allergic Contact,Unspec
+7 ;;^UTILITY(U,$J,358.3,44833,1,4,0)
+8 ;;=4^L23.9
+9 ;;^UTILITY(U,$J,358.3,44833,2)
+10 ;;=^5009125
+11 ;;^UTILITY(U,$J,358.3,44834,0)
+12 ;;=L20.82^^170^2237^3
+13 ;;^UTILITY(U,$J,358.3,44834,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,44834,1,3,0)
+16 ;;=3^Eczema,Flexural
+17 ;;^UTILITY(U,$J,358.3,44834,1,4,0)
+18 ;;=4^L20.82
+19 ;;^UTILITY(U,$J,358.3,44834,2)
+20 ;;=^5009109
+21 ;;^UTILITY(U,$J,358.3,44835,0)
+22 ;;=L20.84^^170^2237^4
+23 ;;^UTILITY(U,$J,358.3,44835,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,44835,1,3,0)
+26 ;;=3^Eczema,Intrinsic
+27 ;;^UTILITY(U,$J,358.3,44835,1,4,0)
+28 ;;=4^L20.84
+29 ;;^UTILITY(U,$J,358.3,44835,2)
+30 ;;=^5009111
+31 ;;^UTILITY(U,$J,358.3,44836,0)
+32 ;;=L51.8^^170^2237^11
+33 ;;^UTILITY(U,$J,358.3,44836,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,44836,1,3,0)
+36 ;;=3^Erythema Multiforme,Other
+37 ;;^UTILITY(U,$J,358.3,44836,1,4,0)
+38 ;;=4^L51.8
+39 ;;^UTILITY(U,$J,358.3,44836,2)
+40 ;;=^336639
+41 ;;^UTILITY(U,$J,358.3,44837,0)
+42 ;;=R23.4^^170^2237^15
+43 ;;^UTILITY(U,$J,358.3,44837,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,44837,1,3,0)
+46 ;;=3^Eschar/Desquamination of Skin
+47 ;;^UTILITY(U,$J,358.3,44837,1,4,0)
+48 ;;=4^R23.4
+49 ;;^UTILITY(U,$J,358.3,44837,2)
+50 ;;=^5019296
+51 ;;^UTILITY(U,$J,358.3,44838,0)
+52 ;;=L49.9^^170^2237^25
+53 ;;^UTILITY(U,$J,358.3,44838,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,44838,1,3,0)
+56 ;;=3^Exfoliation d/t Erythematous Cond w/ 90% or More Body Surface
+57 ;;^UTILITY(U,$J,358.3,44838,1,4,0)
+58 ;;=4^L49.9
+59 ;;^UTILITY(U,$J,358.3,44838,2)
+60 ;;=^5009199
+61 ;;^UTILITY(U,$J,358.3,44839,0)
+62 ;;=L74.9^^170^2237^1
+63 ;;^UTILITY(U,$J,358.3,44839,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,44839,1,3,0)
+66 ;;=3^Eccrine Sweat Disorder,Unspec
+67 ;;^UTILITY(U,$J,358.3,44839,1,4,0)
+68 ;;=4^L74.9
+69 ;;^UTILITY(U,$J,358.3,44839,2)
+70 ;;=^5009296
+71 ;;^UTILITY(U,$J,358.3,44840,0)
+72 ;;=L98.7^^170^2237^16
+73 ;;^UTILITY(U,$J,358.3,44840,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,44840,1,3,0)
+76 ;;=3^Excessive/Redundant Skin/Subq Tissue
+77 ;;^UTILITY(U,$J,358.3,44840,1,4,0)
+78 ;;=4^L98.7
+79 ;;^UTILITY(U,$J,358.3,44840,2)
+80 ;;=^5138778
+81 ;;^UTILITY(U,$J,358.3,44841,0)
+82 ;;=L72.0^^170^2237^7
+83 ;;^UTILITY(U,$J,358.3,44841,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,44841,1,3,0)
+86 ;;=3^Epidermal/Epidermoid Cyst
+87 ;;^UTILITY(U,$J,358.3,44841,1,4,0)
+88 ;;=4^L72.0
+89 ;;^UTILITY(U,$J,358.3,44841,2)
+90 ;;=^5009277
+91 ;;^UTILITY(U,$J,358.3,44842,0)
+92 ;;=L92.3^^170^2238^1
+93 ;;^UTILITY(U,$J,358.3,44842,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,44842,1,3,0)
+96 ;;=3^FB Granuloma Skin/Subcutaneous Tissue
+97 ;;^UTILITY(U,$J,358.3,44842,1,4,0)
+98 ;;=4^L92.3
+99 ;;^UTILITY(U,$J,358.3,44842,2)
+100 ;;=^5009464
+101 ;;^UTILITY(U,$J,358.3,44843,0)
+102 ;;=L66.2^^170^2238^4
+103 ;;^UTILITY(U,$J,358.3,44843,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,44843,1,3,0)
+106 ;;=3^Folliculitis Decalvans
+107 ;;^UTILITY(U,$J,358.3,44843,1,4,0)
+108 ;;=4^L66.2
+109 ;;^UTILITY(U,$J,358.3,44843,2)
+110 ;;=^5009254
+111 ;;^UTILITY(U,$J,358.3,44844,0)
+112 ;;=L73.9^^170^2238^3
+113 ;;^UTILITY(U,$J,358.3,44844,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,44844,1,3,0)
+116 ;;=3^Follicular Disorder,Superficial
+117 ;;^UTILITY(U,$J,358.3,44844,1,4,0)
+118 ;;=4^L73.9
+119 ;;^UTILITY(U,$J,358.3,44844,2)
+120 ;;=^5009286
+121 ;;^UTILITY(U,$J,358.3,44845,0)
+122 ;;=L02.221^^170^2238^5
+123 ;;^UTILITY(U,$J,358.3,44845,1,0)
+124 ;;=^358.31IA^4^2
